Variants_auna.xlsx

In Peru, on 11 February 2023, the Ministry of Health registered 4 million patients infected with COVID-19 and around 219,260 deaths. In 2020, the SARS-CoV-2 virus was acquiring mutations that impacted the properties of transmissibility, infectivity, and immune evasion, leading to new lineages. In the present study, the frequency of COVID-19 variants was determined during 2021 and 2022 in patients treated in the AUNA healthcare network. The methodology used to detect mutations and identify variants was the Allplex^TM SARS-CoV-2 Variants Assay I, II, and VII kit RT-PCR. The frequency of variants was presented by epidemiological weeks. In total, 544 positive samples were evaluated, where the Delta, Ómicron, and Gamma variants were identified. The Delta variant was found in 242 (44.5%) patients between epidemiological weeks 39 and 52 in 2021. In the case of Gamma, it was observed in 8 (1.5%) patients at weeks 39, 41, 43, 45, and 46 of 2021. The Omicron variant was the most frequent with 289 (53.1%) patients during weeks 49 to 52 of 2021 and 1 to 22 of 2022. During weeks 1 through 22 of 2022, it was possible to discriminate between BA. 1 (n=32) and BA.2 (n=82). In conclusion, the rapid identification of COVID-19 variants through the RT-PCR methodology contributes to timely epidemiological surveillance, as well as appropriate patient management.

2023年2月11日，秘鲁卫生部登记的新冠病毒（COVID-19）感染患者达400万人，死亡病例约219260例。2020年，严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）不断发生突变，这些突变会影响其传播性、感染性与免疫逃逸能力，进而催生新的病毒谱系。本研究针对2021至2022年期间在AUNA医疗网络接受诊疗的患者，测定了新冠病毒变异株的流行频率。本次研究采用Allplex™ SARS-CoV-2变异株检测试剂盒I、II及VII型（RT-PCR）完成突变检测与变异株鉴定，变异株的流行频率以流行病学周为单位进行呈现。本研究共评估544份阳性样本，共鉴定出德尔塔（Delta）、奥密克戎（Omicron）与伽马（Gamma）三种变异株。其中德尔塔变异株在2021年第39至52流行病学周期间检出242例，占比44.5%。伽马变异株在2021年第39、41、43、45及46流行病学周期间检出8例，占比1.5%。奥密克戎变异株最为流行，在2021年第49至52流行病学周及2022年第1至22流行病学周期间共检出289例，占比53.1%。在2022年第1至22流行病学周期间，可对BA.1（n=32）与BA.2（n=82）亚型进行区分。综上，采用RT-PCR技术快速鉴定新冠病毒变异株，可为及时开展流行病学监测以及优化患者临床诊疗管理提供重要支撑。